Panbela Therapeutics, Inc.

SNBP

US69833W4042

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 11:05:39 17/06/2024 pm IST			5-day change	1st Jan Change
0.426 ^USD	+3.90%		+3.93%	-97.67%

10/06	Panbela Therapeutics, Inc. Announces Oral Presentation at Digestive Disease Week	CI
17/05	North American Morning Briefing : The "Everything -2-	DJ

Sun BioPharma, Inc. Announces Resignation of J. Robert Paulson, Jr. from the Board of Directors

February 20, 2019 at 08:30 pm IST

On February 16, 2019, J. Robert Paulson, Jr. tendered his resignation, effective immediately, from the Board of Directors of Sun BioPharma, Inc. due to a change in his employment.

Latest news about Panbela Therapeutics, Inc.

Panbela Therapeutics, Inc. Announces Oral Presentation at Digestive Disease Week	10/06	CI
North American Morning Briefing : The "Everything -2-	17/05	DJ
Transcript : Panbela Therapeutics, Inc., Q1 2024 Earnings Call, May 15, 2024	16/05
Panbela Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Certain Stock Options of Panbela Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	01/05	CI
Certain Warrants of Panbela Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	01/05	CI
Certain Common Stock of Panbela Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.	01/05	CI
Panbela Therapeutics, Inc. Announces Interim Data Analysis for its Ongoing ASPIRE Trial Pushed to First Quarter of 2025	22/04	CI
Panbela Announces Poster Presentation At American Association for Cancer Research	18/04	CI
Transcript : Panbela Therapeutics, Inc., Q4 2023 Earnings Call, Mar 26, 2024	27/03
Panbela Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
Panbela Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/03	CI
Panbela Therapeutics, Inc.(OTCPK:PBLA) dropped from S&P TMI Index	11/03	CI
Panbela Therapeutics, Inc.(OTCPK:PBLA) dropped from NASDAQ Composite Index	06/03	CI
Top Midday Decliners	30/01	MT
Traders Cautious Ahead of Fed Meeting, Big Tech Earnings, Driving Muted Premarket Action for US Equity Futures	29/01	MT
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell on Expectations for Unchanged Fed Policy Rate	29/01	MT
Top Premarket Decliners	29/01	MT
Wall Street Set to Open Marginally Lower Friday; December Inflation Data Lower Than Forecast	26/01	MT
US Futures Nudge Lower in Friday's Premarket Ahead of Fed Inflation Data	26/01	MT
Panbela Therapeutics, Inc. Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum	25/01	CI
Panbela Therapeutics, Inc. Announces Publication of Clinical Data Titled: Phase 1 Study of High-Dose DFMO, Celecoxib, Cyclophosphamide and Topotecan for Patients with Relapsed Neuroblastoma	18/01	CI
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	22/12	MT
Sector Update: Health Care	22/12	MT
Top Midday Decliners	22/12	MT

Chart Panbela Therapeutics, Inc.

Duration

Period

More charts

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is involved in enrolling patients in its randomized double-blind placebo-controlled clinical trial for the treatment of pancreatic cancer. The Company's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X). Ivospemin is a polyamine analog designed to induce polyamine metabolic inhibition (PMI). Flynpovi is a combination of CPP-1X (eflornithine) and sulindac. It has a dual mechanism of action whereby it suppresses the synthesis of new polyamines and increases the export and catabolism of polyamines from the diet and microbiome. Eflornithine is being developed as a single-agent tablet or high-dose powder sachet for several indications, including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 diabetes metastatic castration-resistant prostate cancer, and STK-11 mutant NSCLC.

Sector

Biotechnology & Medical Research

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.41 USD

Average target price

25 USD

Spread / Average Target

+5,997.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PANBELA THERAPEUTICS, INC.	-97.67%	19.9L
MODERNA, INC.	+39.42%	5.37TCr
LONZA GROUP AG	+33.67%	3.89TCr
IQVIA HOLDINGS INC.	-7.85%	3.88TCr
CELLTRION, INC.	-10.77%	2.73TCr
ICON PUBLIC LIMITED COMPANY	+12.32%	2.59TCr
ALNYLAM PHARMACEUTICALS, INC.	-18.00%	2.03TCr
UNITED THERAPEUTICS CORPORATION	+34.72%	1.28TCr
MEDPACE HOLDINGS, INC.	+29.12%	1.22TCr
BIO-TECHNE CORPORATION	-3.22%	1.2TCr

Other Biotechnology & Medical Research

Panbela Therapeutics, Inc.

Equities

SNBP

US69833W4042

Biotechnology & Medical Research

Sun BioPharma, Inc. Announces Resignation of J. Robert Paulson, Jr. from the Board of Directors

Latest news about Panbela Therapeutics, Inc.

Chart Panbela Therapeutics, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research